Who invested in Entrada Therapeutics

One round we have observed, with the 7 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$100Mraised across 1 round since 2024, from 1 source

Latest round: Round, $100MJun 2024
Investors: 7

See who backed them

The rounds

Jun 2024
Round$100M
Source recorded

Founders and team

From the SEC filings it signed: 5 on the team.

Dipal DoshiExecutive Officer, Directori
Kory F. WentworthExecutive Officeri
Natarajan F. SethuramanExecutive Officeri
Nathan F. DowdenExecutive Officeri
Nerissa F. KreherExecutive Officeri

On the board, as filediCarole F. NuechterleinJohn F. CrowleyKush M. ParmarPeter F. KimTodd F. Foley

Everyone who backed them

Goldman SachsPrivate equity1round

Wellington ManagementVC firm1round

Janus Henderson InvestorsPrivate equity1round

5AM VenturesVC firm1round

Redmile GroupVC firm1round

TCGPrivate equity1round

TCG CrossoverVC firm1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Entrada Therapeutics

Who invested in Entrada Therapeutics?

Entrada Therapeutics's investors include Goldman Sachs, Wellington Management, Janus Henderson Investors, 5AM Ventures and Redmile Group, and 2 more on record.

How much has Entrada Therapeutics raised?

Entrada Therapeutics has raised $100M across 1 round since 2024.

When did Entrada Therapeutics last raise?

Entrada Therapeutics's most recent round was an Undisclosed round of $100M in Jun 2024.

What was Entrada Therapeutics's biggest round?

Its most recent round, $100M in Jun 2024, is also its largest on record.

Who backed Entrada Therapeutics first?

Entrada Therapeutics's first round on record, in Jun 2024, was backed by Goldman Sachs, Wellington Management and Janus Henderson Investors and 4 others.